Integrin Receptor Inhibitors Products
Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. They exist as heterodimers consisting of alpha and beta subunits. Some alpha and beta subunits exhibit specificity for one another and may be designated as a VLA (very late antigen) member. Heterodimers often preferentially bind certain cell adhesion molecules, or constituents of the ECM. Although they have no catalytic activity, integrins can be part of multimolecular signaling complexes known as focal adhesions.
23 results for "Integrin Receptor Inhibitors" in Products
23 results for "Integrin Receptor Inhibitors" in Products
Integrin Receptor Inhibitors Products
Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. They exist as heterodimers consisting of alpha and beta subunits. Some alpha and beta subunits exhibit specificity for one another and may be designated as a VLA (very late antigen) member. Heterodimers often preferentially bind certain cell adhesion molecules, or constituents of the ECM. Although they have no catalytic activity, integrins can be part of multimolecular signaling complexes known as focal adhesions.
Integrin binding sequence; inhibits integrin receptor function
| Purity: | ≥95% (HPLC) |
α5β1 integrin receptor antagonist
| Purity: | ≥95% (HPLC) |
Minimal recognition sequence for integrin binding; potent integrin inhibitor
| Purity: | ≥95% (HPLC) |
Glycoprotein IIb/IIIa (integrin αIIbβ3) receptor antagonist. Antithrombotic
| Chemical Name: | 4-[4-[4-(Aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid trihydrochloride |
| Purity: | ≥99% (HPLC) |
Potent and selective α5β1 integrin inhibitor
| Chemical Name: | N-(2,6-Dimethylbenzoyl)-O-[3-(2-pyridinylamino)propyl]-L-tyrosine |
| Purity: | ≥98% (HPLC) |
Potent and selective inhibitor of integrins αvβ3 and αvβ5
| Alternate Names: | EMD121974 |
| Purity: | ≥95% (HPLC) |
Dual α9β1/α4β1 integrin inhibitor; preferentially mobilizes HSCs
| Chemical Name: | N-(Benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyrosine sodium salt |
| Purity: | ≥98% (HPLC) |
Highly potent and selective inhibitor of integrin α4β1 (VLA-4)
| Chemical Name: | (2S)-2-[[[(2S)-1-[(3,5-Dichlorophenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-4-[[(2S)-4-methyl-2-[methyl[2-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-1-oxopentyl]amino]butanoic acid |
| Purity: | ≥98% (HPLC) |
Selective inhibitor of integrin α2β1
| Chemical Name: | 1-(4-Fluorophenyl)-N-methyl-N-[4[[(phenylamino)carbonyl]amino]phenyl]-1H-pyrazole-4-sulfonamide |
| Purity: | ≥98% (HPLC) |
αVβ3 and glycoprotein IIb/IIIa (integrin αIIbβ3) inhibitor
| Purity: | ≥95% (HPLC) |
Potent negative allosteric modulator of LFA-1
| Chemical Name: | (5R)-5-[(4-Bromophenyl)methyl]-3-(3,5-dichlorophenyl)-1,5-dimethyl-2,4-imidazolidinedione |
| Purity: | ≥98% (HPLC) |
Selective α4β1 (VLA-4) inhibitor
| Purity: | ≥95% (HPLC) |
Potent αv integrin inhibitor
| Chemical Name: | 3-[[2,5-Dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-4-pyrimidinyl]amino]-N-[(4-methoxyphenyl)sulfonyl]-L-alanine |
| Purity: | ≥97% (HPLC) |
α2 integrin inhibitor; anti-angiogenic
| Chemical Name: | 3-Cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide |
| Purity: | ≥98% (HPLC) |
Potent α2β1 inhibitor; displays antithrombotic activity in vivo
| Chemical Name: | N-[[(4R)-5,5-Dimethyl-3-(phenylsulfonyl)-4-thiazolidinyl]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]amino]-L-alanine |
| Purity: | ≥98% (HPLC) |
Red fluorescent dual α9β1/α4β1 integrin inhibitor comprising BOP conjugated to Janelia Fluor® 646; fluorogenic; photostable
| Chemical Name: | 2-(3-(Azetidin-1-ium-1-ylidene)-7-(azetidin-1-yl)-5,5-dimethyl-3,5-dihydrodibenzo[b,e]silin-10-yl)-5-(((1-((3R,5S)-5-(((S)-1-carboxy-2-(4-((pyrrolidine-1-carbonyl)oxy)phenyl)ethyl)carbamoyl)-1-(phenylsulfonyl)pyrrolidin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)benzoate |
| Purity: | ≥90% (HPLC) |
ανβ6 integrin inhibitor
| Chemical Name: | N-[1-Oxo-5-(2-pyridinylamino)pentyl]-O-(phenylmethyl)-L-seryl-3-(3,5-dichlorophenyl)-β-alanine hydrochloride |
| Purity: | ≥98% (HPLC) |
Potent integrin α4β7 and α4β1 (VLA-4) antagonist; orally bioavailable
| Chemical Name: | (αS)-α-[(2,6-Dichlorobenzoyl)amino]-2',6'-dimethoxy[1,1'-biphenyl]-4-propanoic acid |
| Purity: | ≥98% (HPLC) |
Yellow fluorescent dual α9β1/α4β1 integrin inhibitor comprising BOP conjugated to Janelia Fluor® 549; fluorogenic; photostable
| Chemical Name: | 2-(3-(Azetidin-1-ium-1-ylidene)-6-(azetidin-1-yl)-3H-xanthen-9-yl)-4-(((1-((3R,5S)-5-(((S)-1-carboxy-2-(4-((pyrrolidine-1-carbonyl)oxy)phenyl)ethyl)carbamoyl)-1-(phenylsulfonyl)pyrrolidin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)carbamoyl)benzoate |
| Purity: | ≥85% (HPLC) |
Potent inhibitor of the LFA-1/ICAM-1 interaction
| Chemical Name: | (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one |
| Purity: | ≥99% (HPLC) |
Potent and selective α1β1 inhibitor
| Purity: | ≥95% (HPLC) |
Potent inhibitor of the LFA-1/ICAM interaction
| Chemical Name: | 6-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4,4]non-7-yl]-3-pyridinecarboxylic acid |
| Purity: | ≥98% (HPLC) |
α4β1 (VLA-4) antagonist
| Chemical Name: | 1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediacetic acid |
| Purity: | ≥98% (HPLC) |
